Aviragen Therapeutics (AVIR) Tops Q2 EPS by 18c
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 11/1/2026
- Wall Street closes sharply lower as AI cash burn fears spark tech selloff
- Amazon burns cash, Intel flags weak PC demand as AI boom's costs ripple across markets
- Bitcoin, cryptocurrency prices fall after Binance reports security issue
- Higher yields now hurting AI stock bull as bond markets police capex: BofA
- Oil jumps 2%, settles at 6-month highs on fears of escalation in Iran
Tweet
Share
E-mailGet Alerts AVIR Hot Sheet
Join SI Premium – FREE
Aviragen Therapeutics (NASDAQ: AVIR) reported Q2 EPS of ($0.48), $0.18 better than the analyst estimate of ($0.66).
For earnings history and earnings-related data on Aviragen Therapeutics (AVIR) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Goldman Sachs Updates US Conviction List Directors' Cut
- These 3 EU chip stocks screen as most de-risked sector bets: UBS
- Citi raises General Dynamics price target to $400, keeps Neutral
Create E-mail Alert Related Categories
EarningsRelated Entities
Earnings, Maynard Um, Mark Zuckerberg, ARKSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
